© 2019  Cord Blood Association
The presentations at the 2019 Cord Blood Connect international congress are the property of the Cord Blood Association. They are posted for personal reference by the website visitor. Download, reproduction or any other use of the audio, video or visuals of these presentations is prohibited without the written permission of the Cord Blood Association.
Friday, September 13
Opening Session and Congress Overview
‍Joanne Kurtzberg, Colleen Delaney and Karen Ballen
Emerging Technologies in Cell Engineering: Development of Novel Cell Therapies
‍Colleen Delaney
Novel Strategies To Improve Cord Blood Transplant Outcomes in Adults with Hematologic Malignancies
‍Juliet Barker
Tresosulfan-based Conditioning Regimens for Malignant Disease
‍Filippo Milano
Contract Language and Release of Products from Family Banking Programs
‍David Portnoy
Establishment of a Cellular Therapy Product Stability Program: Summarizing the Work of the AABB-ISCT Joint Working Group
Aby J. Mathew
Life Sciences: Combining Reproductive and Stem Cell Services
‍Jaime Shamonki
The Use of Umbilical Cord Blood for Autologous Transfusions in Neonatal Cardiac Surgery
‍Kyrylo Chasovskyi
Cord Blood as Adoptive Immunotherapy for Refractory AML: Bridge to Transplant
‍Andromachi Scaradavou
Learning from the Past
‍Eliane Gluckman
Lifetime Achievement Award and Keynote Lecture: How To Enhance the Efficacy of Cord Blood Hematopoietic Cell Transplantation
‍Hal Broxmeyer 
Impact of HLA and Haplotype Matching on Outcomes after Single-Unit Umbilical Cord Blood Transplantation
‍Junya Kanda
Selection Criteria of Double Cord Blood Transplants
‍Vanderson Rocha
Consenting for Cord Blood Donation in the Modern Era of Commercialization
‍Marcie Finney
Adult Frailty Trial
‍Josh Hare
Consolidation and Globalization of Cord Blood
‍James Alexis Mendez
Cord Blood-Derived Mesenchymal Cells for Foot Ulcers
‍Brian Freed
Striking the Right Cord: an Industry Perspective
‍Ronit Simantov
Saturday, September 14
Why I Am Not Doing Cord Blood Transplants: from the Adult HCT Transplant Program Perspective
‍Krishna Komanduri
Overview of Cellular Immunotherapies and the Importance of Cord Blood as a Source of Starting Material for Immunotherapies
‍Saar Gill
East Mediterranean Blood and Marrow Transplant – EBMT
‍Hassan El Solh
World Marrow Donor Association-NetCord (WMDA-NetCord)
‍Lydia Foeken
Clinical Trials Design: Real-World Evidence and Case Histories
‍Jesse Troy
Panel Discussion: The Best Way To Maintain an Appropriate Inventory
‍Alejandro Madrigal, Kate Falco Girard and Erika Narr
Choosing Between Alternative Donors: the Pediatric HCT Transplant Program Perspective
‍Michael Verneris
Cord Blood Transplantation for Non-Malignant Diseases Using a Serotherapy-Free Conditioning Regimen (with Immune Reconstitution Data )
‍Cary Martinez
Cord Blood Transplantation for b-thal: Taiwan Study
‍Anthony Filiano
Human Cytokine-Induced Memory-Like Natural Killer Cells and Clinical Applications
Rizwan Romee
Center for International Blood and Marrow Transplant Research (CIBMTR)
‍Bronwen Shaw
Two Bayesian Clinical Trial Designs for Precision Medicine in Oncology
‍Peter Thall
Novel Ideas in Cord Blood Selection
‍Sergio Querol Giner
Oral Abstracts and Best Abstract Awards

Point/Counterpoint Debate
‍Maria Ester Bernardo and Jaap Boelens
Eurocord
‍Eliane Gluckman
Japan Society for Hematopoietic Cell Transplantation/Japanese Data Center for Hematopoietic Cell Transplantation (JSHCT/JDCHCT)
‍Junya Kanda
How To Design a Multi-Center Trial with Little Funding and No Involvement of BMT/CTN
‍Bronwen Shaw
Strategies To Ensure that New Public Units Meet Clinical Needs without Compromising Bank Sustainability
‍Heidi Elmoazzen
Sunday, September 15
FDA's Approach to Products Derived from Cord Blood
‍Peter Marks
Ethical and Regulatory Issues (Panel Discussion)
‍Morey Kraus, Richard Jennings, Joanne Kurtzberg, Peter Marks, David Portnoy, Mark Portnoy and Jeremy Sugarman
Defining Real World Release Specifications for Use of Cord Blood and Cord Tissue-Derived Products in the Clinic
‍Joanne Kurtzberg
Ethical Responsibilities of Key Stakeholders In Cord Blood Banking and Use
Jeremy Sugarman
Impact of Zika Virus on Public Cord Blood Banking: Reconciling CDC Travel Warnings with Donor Screening
‍Beth Shaz
What Is the Role, if Any, of Expanded Access Protocols in Supporting Applications for Licensure of Novel Cell Therapy Products
‍Peter Marks
Accelerating the Uptake of Cord Blood-Derived Therapies by Improving Quality through Manufacturing Automation
‍Jon Ellis
Product Release Tests and Release Criteria (Interactive Panel)
Jon Ellis, Linda Kelley, Joanne Kurtzberg, Peter Marks and Beth Shaz
The following presentations are not available, by agreement with the authors:
Characterization of MSCs from Multiple Tissue Sources  –  Krishnendu Roy  
Cord Blood MSC Manufacturing and Clinical Applications  –  Jessica Sun
Cord Blood Regulatory T-Cells: from Bench to Bedside  –  Simrit Parmar  
‍CordBlood Therapies, a Game Changer for Children with Brain Disorders – Joanne Kurtzberg
NYSCF:Partnering with Industry and Academia to Accelerate Cures  –  Frederick (Rick) Monsma  
Mechanisms of Immune Evasion and Relapse after HCT  –  Luca Vago
Comparison of Haplo vs. Cord Blood HCT in Pediatrics  –  Mary Eapen
Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease  –  Agnieszka Czechowicz
The Role of Cord Blood Monocytes in Modulating Non-Malignant Diseases  –  Anthony Filiano
Leveraging Natural Killer Cell Immunotherapy through Cytokine-Bearing Antigen-Specific TriKE Molecules  –  Martin Felices
Clinical Trials Design: Real-World Evidence and Case Histories  –  Jesse Troy
Development of a Therapeutic NK Cell Product Generated from Cord Blood CD34+ Cells Expanded on Notch Ligand  – Carrie Stoltzman  
Characterization of MSCs from Multiple Tissue Sources  –  Krishnendu Roy  
Cord Blood MSC Manufacturing and Clinical Applications  –  Jessica Sun
Cord Blood Regulatory T-Cells: from Bench to Bedside  –  Simrit Parmar  
‍Cord Blood Therapies, a Game Changer for Children with Brain Disorders – Joanne Kurtzberg
NYSCF: Partnering with Industry and Academia to Accelerate Cures  –  Frederick (Rick) Monsma  
Mechanisms of Immune Evasion and Relapse after HCT  –  Luca Vago
Comparison of Haplo vs. Cord Blood HCT in Pediatrics  –  Mary Eapen
Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease  –  Agnieszka Czechowicz
The Role of Cord Blood Monocytes in Modulating Non-Malignant Diseases  –  Anthony Filiano
Leveraging Natural Killer Cell Immunotherapy through Cytokine-Bearing Antigen-Specific TriKE Molecules  –  Martin Felices
Clinical Trials Design: Real-World Evidence and Case Histories  –  Jesse Troy
Development of a Therapeutic NK Cell Product Generated from Cord Blood CD34+ Cells Expanded on Notch Ligand  – Carrie Stoltzman  
‍